ASCO 2022 | Advances in managing KRASG12C- and EGFR-mutated NSCLC

Joshua K. Sabari, MD, NYU Langone Health, New York, NY, describes novel developments in targeted therapies for patients with non-small cell lung cancer (NSCLC). Dr Sabari highlights combining KRASG12C inhibitors with existing therapies to enhance efficacy and treatment outcomes, as well as novel EFGR-TKIs such as osimertinib. The phase I CHRYSALIS trial (NCT02609776) assessing amivantamab, an EGFR-MET bispecific antibody, with lazertinib will also attempt to elucidate novel treatment strategies for patients who progress on third generation TKIs. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.